Drugs / Insulin Lispro
Insulin Lispro
also known as
Humalog · lispro · LY900014 · insulin lispro protamine suspension · Lispro Insulin · URLi · Humalog (lispro) · LIS · +21 more
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | HUMALOG KWIKPEN | — | 2000-04-04 – 2012-10-14 | fda.gov ↗ |
| Approved | US (FDA) | HUMALOG KWIKPEN | — | 1996-06-14 | fda.gov ↗ |
| Approved | EU (EMA) | Humalog | — | 1996-04-30 | europa.eu ↗ |
Trials 108 · started per year
today
EU approved 1996
US approved 1996
1
2
4
2
1
4
6
9
3
9
3
2
7
12
7
3
5
6
8
5
2
2
4
1
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 130 trials | ||||||
| Phase 1 | NCT07090824 | Oct 2025 → May 2026 | type 1 diabetes mellitus | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT05262387 | Feb 2022 → Mar 2023 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04501107 | Aug → Nov 2020 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT04161976 | Dec 2019 → Jul 2020 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03741478 | Oct 2019 → Jul 2026 overdue | — | Centre for Addiction and Mental Health | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04235439 | Apr → Jul 2019 | diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT03616977 | Aug → Oct 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02623478 | Jan → Apr 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT02623465 | Jan → Apr 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT02623452 | Jan → Apr 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03334448 | Dec 2017 → Mar 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03367390 | Nov 2017 → Feb 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03232983 | Aug → Nov 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03179332 | Jun → Sep 2017 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02752087 | Apr → May 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02603510 | Nov 2015 → Apr 2016 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02562326 | Sep 2015 → Jan 2016 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02470637 | Jun → Sep 2015 | type 1 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02317575 | Jan → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02293551 | Dec 2014 → Sep 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02197520 | Jul 2014 → Jun 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02152384 | Jun → Dec 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02111083 | May → Aug 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01981031 | Nov → Dec 2013 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02131948 | Nov 2013 → Jul 2014 | diabetes mellitus | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT01871493 | Jun → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01792323 | Aug → Nov 2011 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 1 | NCT00979875 | Sep 2009 → Feb 2010 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00862849 | Mar → Jun 2009 | diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00803972 | Nov 2008 → Aug 2009 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03383822 | Sep 2015 → Jul 2017 | type 2 diabetes mellitus | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT02213146 | Aug → Dec 2014 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT04542148 | Feb 2022 → Nov 2025 overdue | gestational diabetes, type 2 diabetes mellitus | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04585776 | Oct 2020 → May 2021 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03938740 | Mar → Dec 2019 | type 1 diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03682640 | Sep 2018 → Dec 2021 | type 1 diabetes mellitus | Uppsala University | Unknown | No outcome recorded |
| Phase 2 | NCT02221323 | Sep → Nov 2014 | diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02146651 | May → Jul 2014 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 2 | NCT01756105 | Jun 2012 → Feb 2018 | gestational diabetes | University Hospital, Strasbourg, France | Terminated | No outcome recorded |
| Phase 2 | NCT01194245 | Aug 2010 → Aug 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01194258 | Aug 2010 → Aug 2011 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00883558 | May 2009 → Feb 2010 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00774800 | Oct 2008 → Mar 2009 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00747006 | Sep 2008 → Feb 2011 | type 1 diabetes mellitus, type 2 diabetes mellitus | Mannkind Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00662857 | Apr → Nov 2008 | type 1 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00553488 | Sep → Dec 2007 | type 1 diabetes mellitus | Becton, Dickinson and Company | Completed | No outcome recorded |
| Phase 2 | NCT01000922 | Jun 2006 → Jan 2008 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 2 | NCT00063128 | Apr 2003 → Apr 2004 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03262116 | Mar → Jul 2019 | type 1 diabetes mellitus | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT00447213 | Apr 2007 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT04605991 | Nov 2020 → Feb 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04254380 | Dec 2019 → Jan 2020 | type 1 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Withdrawn | No outcome recorded |
| Phase 3 | NCT03433677 | Feb → Sep 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02229227 | Nov 2014 → Jul 2017 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02192424 | Jul 2014 → Aug 2020 | type 2 diabetes mellitus | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT01755468 | Apr 2013 → Oct 2017 | type 2 diabetes mellitus | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT01481779 | Jan 2012 → May 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01136746 | Mar → Nov 2011 | hyperglycemia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01134107 | Nov 2010 → Dec 2011 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01110746 | Feb → Jun 2010 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00700622 | May 2008 → Nov 2009 | type 1 diabetes mellitus | Mannkind Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT00666718 | Apr 2008 → Feb 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00494013 | Aug 2007 → Sep 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00510952 | Aug 2007 → Oct 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00487240 | Jun 2007 → Aug 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00191581 | Mar 2005 → Apr 2006 | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00097071 | Oct 2004 → May 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00071448 | Jun 2002 → Jun 2004 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 425 trials | ||||||
| Phase 4 | NCT06600776 | Oct 2024 → Sep 2025 overdue | type 1 diabetes mellitus | Tel-Aviv Sourasky Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04019821 | Jan 2020 → Jan 2023 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT04157738 | Nov 2019 → Dec 2020 | type 1 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03670641 | Mar 2019 → Jul 2020 | type 2 diabetes mellitus | Sandra Sobel | Completed | No outcome recorded |
| Phase 4 | NCT03328845 | Jan 2017 → Nov 2020 | type 1 diabetes mellitus | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Completed | No outcome recorded |
| Phase 4 | NCT03509324 | Mar → Jun 2015 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02276859 | Oct 2014 → Sep 2015 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT04739241 | Jan 2014 → Apr 2018 | type 2 diabetes mellitus | Consorci Sanitari Integral | Completed | No outcome recorded |
| Phase 4 | NCT02165566 | Mar 2013 → Mar 2014 | hyperglycemia | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 4 | NCT01215955 | Dec 2010 → Jan 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01159938 | Oct 2010 → Feb 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01121835 | Feb 2010 → Mar 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01613807 | Oct 2008 → Jun 2010 | gestational diabetes | Sansum Diabetes Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00664534 | Apr 2008 → Nov 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00607087 | Jan 2008 → Jun 2009 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00420095 | Jan 2007 → Jan 2008 | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00841919 | Dec 2006 → Mar 2009 | type 2 diabetes mellitus | Cook County Health | Completed | No outcome recorded |
| Phase 4 | NCT00393705 | Oct 2006 → Mar 2009 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00377858 | Aug 2006 → Sep 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00110370 | Apr 2004 → Apr 2006 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00191464 | Dec 2003 → Sep 2005 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00191178 | Aug 2003 → Jul 2005 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT02962921 | Feb → May 2003 | cardiac ventricle disorder, diabetes mellitus | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 4 | NCT00191282 | Oct 2002 → Oct 2007 | acute myocardial infarction, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00036504 | Aug 2001 → Aug 2002 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT06419777 | Sep 2024 → May 2026 overdue | gestational diabetes | Thomas Jefferson University | Recruiting | No outcome recorded |
| — | NCT06251635 | Jun 2024 → Aug 2026 overdue | type 2 diabetes mellitus | Centre for Addiction and Mental Health | Recruiting | No outcome recorded |
| — | NCT06765655 | Apr 2024 → Jan 2025 overdue | hyperglycemia | St. Peter's Hospital, Albany, NY | Enrolling by invitation | No outcome recorded |
| — | NCT05571878 | Sep 2021 → May 2025 | major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT03229850 | Feb 2021 → Jan 2025 | diabetes mellitus, localized lipodystrophy | Graydon Meneilly | Withdrawn | No outcome recorded |
| — | NCT04200313 | Mar 2020 → Oct 2021 | type 1 diabetes mellitus | Jaeb Center for Health Research | Completed | No outcome recorded |
| — | NCT03604575 | Aug → Dec 2016 | — | Geropharm | Completed | No outcome recorded |
| — | NCT03102476 | Jun 2016 → Feb 2018 | type 1 diabetes mellitus | University of Hull | Completed | No outcome recorded |
| — | NCT02518022 | Sep 2015 → Jun 2016 | hypoglycemia, type 1 diabetes mellitus | Kinderkrankenhaus auf der Bult | Withdrawn | No outcome recorded |
| — | NCT02248454 | Sep 2014 → Apr 2015 | type 1 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| — | NCT01636596 | Sep 2013 → Jan 2015 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Louisiana State University Health Sciences Center Shreveport | Withdrawn | No outcome recorded |
| — | NCT01974544 | May 2013 → Dec 2015 | type 2 diabetes mellitus | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT01303042 | Feb 2011 → Dec 2013 | type 2 diabetes mellitus | Aichi Gakuin University | Unknown | No outcome recorded |
| — | NCT01149005 | Jun 2010 → Jun 2015 | cystic fibrosis, glucose intolerance, lung disorder | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT01045954 | Jan → Aug 2010 | type 1 diabetes mellitus | Diabetes Care Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 177 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02012465 Background | Sep 2013 → May 2015 | hyperglycemia, lymphoma, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 147 trials | ||||||
| Phase 1 | NCT06945406 Background | May 2025 → Dec 2026 expected | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05689424 Comparator | Feb 2025 → Jun 2026 overdue | type 1 diabetes mellitus | University of California, San Diego | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06280703 Background | May 2024 → Sep 2026 expected | type 1 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05373186 Comparator | May → Dec 2022 | — | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT05373199 Comparator | May → Oct 2022 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT04972175 Comparator | Jul 2021 → Jun 2022 | type 1 diabetes mellitus | Michael Tsoukas | Unknown | No outcome recorded |
| Phase 1 | NCT06153329 Comparator | Jun 2021 → Jun 2022 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04276207 Comparator | Feb → Aug 2020 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04049123 Comparator | Nov 2019 → Oct 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03916640 Comparator | Jan → Mar 2019 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT03512236 Comparator | Apr 2018 → Feb 2019 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT03465878 Comparator | Mar 2018 → Nov 2019 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03449433 Comparator | Mar → Aug 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03407118 Comparator | Feb → Jun 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03341299 Comparator | Nov 2017 → Apr 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03341312 Comparator | Nov 2017 → Mar 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03286751 Comparator | Oct 2017 → Feb 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03305822 Comparator | Oct → Dec 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03170544 Background | Aug 2017 → Nov 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03166124 Comparator | May → Nov 2017 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03056456 Comparator | Feb → Jun 2017 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02942654 Comparator | Nov → Dec 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02915250 Comparator | Oct 2016 → Jun 2017 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02770521 Comparator | May → Jul 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02703350 Comparator | Mar → Jul 2016 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02703324 Comparator | Mar → Aug 2016 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02703337 Comparator | Mar → Aug 2016 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02660502 Comparator | Jan → May 2016 | — | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02636361 Comparator | Dec 2015 → Feb 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02562313 Comparator | Sep 2015 → Nov 2016 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02500979 Background | Aug 2015 → Aug 2016 | type 1 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02528396 Comparator | Aug → Dec 2015 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02529293 Comparator | Aug → Nov 2015 | — | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02525744 Comparator | Aug → Oct 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02514850 Comparator | Jul → Nov 2015 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02344992 Comparator | Jan → Jun 2015 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02029924 Comparator | Dec 2013 → Mar 2014 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02273258 Comparator | Mar → Jul 2013 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01811849 Comparator | Aug → Dec 2012 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 1 | NCT01638325 Comparator | Jul → Sep 2012 | — | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT01908894 Comparator | Feb → Mar 2012 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 1 | NCT01334151 Comparator | Mar → Aug 2011 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 1 | NCT01035801 Comparator | Aug 2010 → Mar 2011 | type 1 diabetes mellitus | Biocon Limited | Terminated | No outcome recorded |
| Phase 1 | NCT00810589 Comparator | Nov → Dec 2008 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 1 | NCT00705536 Comparator | Dec 2007 → Feb 2008 | diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00652288 Comparator | Apr 2007 → Sep 2011 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01201278 Comparator | — | type 1 diabetes mellitus | Hompesch, Marcus, M.D. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02739906 Comparator | Apr → Aug 2016 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1/2 | NCT02716610 Comparator | Oct 2013 → Jan 2014 | type 2 diabetes mellitus | Dance Biopharm Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02713841 Comparator | May → Jul 2013 | type 1 diabetes mellitus | Dance Biopharm Inc. | Completed | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT06238778 Comparator | Jan 2024 → Oct 2025 overdue | type 1 diabetes mellitus | Diasome Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04816890 Comparator | Mar 2021 → Feb 2022 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 2 | NCT03760640 Comparator | Feb → Oct 2019 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT02846831 Comparator | Jan 2019 → Jan 2020 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT04100473 Comparator | Apr → Aug 2018 | type 2 diabetes mellitus | Dance Biopharm Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02488616 Comparator | Mar → Nov 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT03307512 Comparator | Feb 2018 → Jul 2019 | — | Dance Biopharm Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02490098 Comparator | Jan → Jul 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT03156361 Comparator | May 2017 → Jan 2018 | type 1 diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03096392 Comparator | Apr → Nov 2017 | type 1 diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02971228 Background | Nov 2016 → May 2017 | type 1 diabetes mellitus | Zealand Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02855307 Comparator | Sep 2016 → Dec 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02794155 Comparator | Jun 2016 → Apr 2018 | type 1 diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02798250 Comparator | Jun 2016 → Mar 2017 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02626936 Comparator | Jan → Jun 2016 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02416765 Comparator | May → Oct 2015 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01662921 Comparator | Apr 2013 → Jan 2015 | gestational diabetes | Sansum Diabetes Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01686620 Comparator | Aug 2012 → Jun 2013 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 2 | NCT01067118 Comparator | Apr 2010 → Jan 2011 | diabetes mellitus | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00916357 Comparator | Jul → Nov 2009 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02846857 Comparator | ? → Jul 2019 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 341 trials | ||||||
| Phase 3 | NCT06931041 Comparator | Feb 2024 → Jun 2025 overdue | Sjogren syndrome, dry eye syndrome | Instituto de Oftalmología Fundación Conde de Valenciana | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05462756 Background | Aug 2022 → Feb 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05834868 Comparator | May 2022 → Dec 2024 | type 2 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT07282054 Comparator | Apr 2022 → Jan 2025 | type 1 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04974528 Comparator | Sep 2021 → Oct 2024 | type 1 diabetes mellitus, type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04537923 Comparator | Oct 2020 → Oct 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03952130 Comparator | May 2019 → Jan 2022 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03952143 Comparator | May 2019 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03740919 Comparator | Apr 2019 → Jul 2021 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03830281 Comparator | Feb 2019 → Jan 2020 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03338023 Background | Mar 2018 → Mar 2020 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03214367 Comparator | Jul 2017 → Sep 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03214380 Comparator | Jul 2017 → Aug 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02294474 Comparator | Jan 2015 → Feb 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02273180 Comparator | Oct 2014 → Dec 2015 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02194595 Comparator | Sep 2014 → Dec 2021 | type 2 diabetes mellitus | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT01792284 Background | Feb 2013 → Apr 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03507829 Comparator | Nov 2012 → May 2018 | hyperglycemia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT01680185 Comparator | Aug 2012 → May 2018 | hyperglycemia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT01621178 Background | Jul 2012 → Jun 2016 | chronic kidney disease, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01398670 Comparator | Feb 2012 → Mar 2013 | type 1 diabetes mellitus | Wockhardt | Withdrawn | No outcome recorded |
| Phase 3 | NCT01454284 Background | Jan 2012 → Feb 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01468987 Background | Dec 2011 → Aug 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01474538 Comparator | Dec 2011 → Feb 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01421147 Background | Aug 2011 → Aug 2012 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01191268 Background | Nov 2010 → Feb 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01109316 Comparator | Apr 2010 → Aug 2011 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00993473 Background | Oct 2009 → Mar 2011 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00960661 Comparator | Sep 2009 → Aug 2012 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00976391 Comparator | Sep 2009 → Oct 2011 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00849576 Comparator | Apr → Aug 2008 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00560417 Comparator | Nov 2007 → Dec 2009 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00467376 Comparator | Jan 2007 → Jun 2008 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00356109 Comparator | Aug 2006 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00348374 Comparator | Jun 2006 → Aug 2008 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00325364 Comparator | Apr 2006 → May 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00231725 Background | Sep 2005 → Apr 2006 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00127634 Comparator | Jul 2005 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00115570 Comparator | Apr 2005 → Nov 2006 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00046501 Background | Nov 2002 → Feb 2005 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01336751 Comparator | Jul 2001 → Dec 2002 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 445 trials | ||||||
| Phase 4 | NCT07109245 Background | Dec 2025 → Aug 2028 expected | acute insulin response | Centre for Addiction and Mental Health | Recruiting | No outcome recorded |
| Phase 4 | NCT05457933 Background | Jul 2022 → Jan 2023 | coronary artery disorder, type 2 diabetes mellitus | Medanta, The Medicity, India | Completed | No outcome recorded |
| Phase 4 | NCT05579119 Background | Jul 2022 → Aug 2023 | type 2 diabetes mellitus | Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social | Completed | No outcome recorded |
| Phase 4 | NCT04783376 Comparator | Apr → Nov 2021 | type 1 diabetes mellitus | Sohag University | Completed | No outcome recorded |
| Phase 4 | NCT04416269 Background | Aug 2020 → Mar 2026 overdue | diabetes mellitus | Emory University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04196231 Comparator | Nov 2019 → Sep 2020 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT04124302 Background | Oct 2019 → Mar 2024 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT03660553 Comparator | Oct 2018 → Jun 2022 | type 2 diabetes mellitus | University of Miami | Terminated | No outcome recorded |
| Phase 4 | NCT04690309 Comparator | Jul 2018 → Dec 2020 | type 5 diabetes mellitus | Polish Society of Diabetology | Unknown | No outcome recorded |
| Phase 4 | NCT03563794 Comparator | Jun 2018 → Jun 2019 | type 2 diabetes mellitus | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 4 | NCT03350984 Comparator | Nov 2017 → Jul 2018 | type 2 diabetes mellitus | University of Guanajuato | Completed | No outcome recorded |
| Phase 4 | NCT03260868 Background | Sep 2017 → Nov 2018 | type 1 diabetes mellitus | Sanofi | Terminated | No outcome recorded |
| Phase 4 | NCT02811484 Background | Jun 2016 → Jun 2018 | type 2 diabetes mellitus | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02741687 Background | Jun 2016 → Apr 2017 | hyperglycemia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02688933 Background | May 2016 → Jun 2017 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02690883 Comparator | Apr 2016 → Dec 2019 | diabetic kidney disease | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02685449 Comparator | Feb 2016 → Feb 2018 | type 1 diabetes mellitus | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT02556918 Background | Jan 2016 → Nov 2018 | hyperglycemia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02443402 Background | Jan → Dec 2016 | coronary artery disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03463564 Comparator | Jan 2016 → Dec 2026 expected | type 1 diabetes mellitus | University of Campania Luigi Vanvitelli | Recruiting | No outcome recorded |
| Phase 4 | NCT02526810 Comparator | Jul 2015 → Aug 2016 | type 2 diabetes mellitus | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT02250794 Comparator | Oct 2014 → May 2015 | type 2 diabetes mellitus | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02004366 Background | Jan 2014 → Feb 2017 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03662334 Background | Oct 2013 → Feb 2014 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01971047 Comparator | Oct 2013 → Sep 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Emory University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01845831 Comparator | Aug 2013 → Apr 2016 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02189395 Comparator | Apr 2013 → Apr 2017 | type 2 diabetes mellitus | Riverside University Health System Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01848990 Background | Mar 2013 → Feb 2014 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01524705 Comparator | Aug 2012 → Jul 2014 | type 2 diabetes mellitus | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT01776788 Comparator | Aug 2012 → Feb 2015 | type 2 diabetes mellitus | The First Affiliated Hospital of Xiamen University | Completed | No outcome recorded |
| Phase 4 | NCT01526733 Background | Dec 2011 → Aug 2012 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01378117 Comparator | Aug 2011 → May 2012 | hyperglycemia, type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01175824 Comparator | Apr 2011 → Nov 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01175811 Comparator | Feb 2011 → Nov 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01269034 Comparator | Dec 2010 → Jan 2017 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01810952 Background | Sep 2010 → Sep 2013 | diabetes mellitus, hyperglycemia | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01184014 Background | Aug 2010 → Aug 2012 | hyperglycemia | HealthPartners Institute | Completed | No outcome recorded |
| Phase 4 | NCT00985712 Background | Oct 2009 → Jul 2011 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01269047 Comparator | Aug 2009 → Aug 2016 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00548808 Comparator | Nov 2007 → Aug 2009 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00505882 Background | Jul 2007 → Dec 2008 | type 1 diabetes mellitus | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT00467649 Comparator | May 2007 → Apr 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00356421 Comparator | Nov 2006 → Jun 2008 | type 1 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT00279201 Comparator | Dec 2005 → Nov 2009 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00461331 Comparator | Oct 2004 → Jun 2007 | type 1 diabetes mellitus | Tulane University Health Sciences Center | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT07171684 Comparator | Nov 2025 → Oct 2026 expected | gestational diabetes | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| — | NCT06419803 Comparator | Sep 2024 → May 2026 overdue | gestational diabetes | Thomas Jefferson University | Recruiting | No outcome recorded |
| — | NCT06532461 Comparator | Jul 2024 → Dec 2026 expected | type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Recruiting | No outcome recorded |
| — | NCT05893797 Background | Oct 2023 → Sep 2024 | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT05660941 Comparator | Jul 2023 → May 2024 | type 1 diabetes mellitus | Manchester University NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT05508061 Comparator | Oct 2022 → Mar 2023 | type 1 diabetes mellitus | Inreda Diabetic B.V. | Completed | No outcome recorded |
| — | NCT04243629 Background | Nov 2021 → Apr 2024 | hyperglycemia, type 1 diabetes mellitus | McGill University | Unknown | No outcome recorded |
| — | NCT04965051 Comparator | Aug 2021 → Dec 2023 | type 1 diabetes mellitus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT04484779 Background | Jul → Dec 2020 | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT04031599 Comparator | Jul 2020 → Nov 2021 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| — | NCT03890003 Background | Mar → May 2019 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT03849612 Background | Feb → Mar 2019 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT03848767 Background | Feb → Apr 2019 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT03743285 Background | Nov 2018 → Jan 2019 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT02155023 Background | Jan 2014 → Jan 2015 | diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| — | NCT01621776 Comparator | Jun 2011 → Aug 2012 | type 1 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| — | NCT00428207 Comparator | Feb 2007 → Aug 2008 | type 1 diabetes mellitus | Joslin Diabetes Center | Terminated | No outcome recorded |
| — | NCT00574405 Comparator | Apr 2005 → Mar 2010 | type 1 diabetes mellitus | Arkansas Children's Hospital Research Institute | Completed | No outcome recorded |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 297 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin lispro | “The purpose of the study is to compare the human insulin inhalation powder plus insulin glargine with injected insulin (regular human insulin or insulin lispro) plus insulin...” NCT00447213 ↗191“Comparison of 2-Hour Postprandial Blood Glucose Excursion in Response to a Standard Test Meal in Insulin-Requiring Diabetic Patients Treated Twice Daily With Either Insulin...” NCT00191581 ↗ “Patients originally receiving insulin glargine were enrolled in intensification arm A and were randomized to receive BBT (insulin glargine once daily plus mealtime insulin...” PMID 20685497 ↗ May 2010 “Types of insulin: insulin lispro (Humalog 100 IU/mL) as fast-acting insulin and regular insulin (Humulin R) as regular insulin (Eli Lilly and Company, Indianapolis, IN, USA).” NCT04783376 ↗ “Patients were randomized to a two-period crossover study schedule, ingesting breakfast, with or without insulin lispro (to induce low or high postprandial glycemia).” PMID 26731258 ↗ Jan 2016 “Commercially available U-200 Humalog (insulin lispro) diluted 1:1 with a dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration.” NCT07090824 ↗ “In this context, we sought to evaluate the vascular function effects of adding the GLP1-RA exenatide or meal insulin lispro to basal glargine therapy in early T2DM.” PMID 36894921 ↗ Mar 2023 “Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.” NCT03463564 ↗ “Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.” NCT00063128 ↗ “Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening.” NCT02688933 ↗ “Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks.” NCT04974528 ↗ “25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only” NCT01121835 ↗ “patients continued OAMs and were randomized to AIR insulin (n = 208) or insulin lispro (n = 203) before meals” PMID 19772446 ↗ Sep 2009 “receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care” PMID 36170500 ↗ Sep 2022 “This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood sugar.” NCT03232983 ↗ “BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin Lispro.” NCT01981031 ↗ “single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation” NCT02716610 ↗ “receive AIR insulin or SC insulin (regular human insulin or insulin lispro) at mealtimes.” PMID 19772449 ↗ Sep 2009 “RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.” NCT00662857 ↗ “compared insulin lispro with meals and basal insulin glargine (intervention) vs” PMID 21454236 ↗ Sep 2011 “BioChaperone insulin lispro U-200 and BioChaperone insulin lispro U-100” NCT02529293 ↗ “a new formulation of insulin lispro when given by an insulin pump” NCT04161976 ↗ “simultaneous injections of insulin lispro (Humalog®) and placebo” NCT03512236 ↗ “Insulin lispro 100 Units/mL, average dose: 10-30 U/day” NCT05457933 ↗ “Basal insulin glargine and pre-meal insulin lispro” NCT01755468 ↗ “basal insulin glargine and pre-meal insulin lispro” NCT02192424 ↗ “preprandial injectable insulin (insulin lispro)” NCT00356109 ↗ “thrice-daily prandial insulin lispro” PMID 24898300 ↗ Jun 2014 “Humalog insulin lispro U-100” NCT02500979 ↗ “biphasic insulin lispro 50%” NCT04739241 ↗ “Insulin Lispro (Humalog®)” NCT00071448 ↗ “Insulin Lispro (Humalog®)” NCT02029924 ↗ “Insulin Lispro (Humalog®)” NCT02213146 ↗ “Insulin lispro” NCT00705536 ↗ “Insulin lispro” NCT05565976 ↗ |
| Known as | BioChaperone insulin lispro | “Single subcutaneous administration of BioChaperone® insulin lispro” NCT03179332 ↗ |
| Known as | GL-Lis | “lispro (GL-Lis, n = 38)” PMID 37735841 ↗ Sep 2023 |
| Known as | HDV-bound LIS | “The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS).” NCT05689424 ↗ |
| Known as | Hepatic Directed Vesicles + Insulin Lispro | “The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS).” NCT05689424 ↗ |
| Known as | Hlog | “The aim of this multicenter, prospective, randomized, crossover trial is to compare, in critical care patients receiving insulin infusion therapy (IIT), the pharmacodynamic of...” PMID 25466315 ↗ Oct 2014 |
| Known as | Humalog | “This is a double-blind, randomised, controlled, two-period crossover phase Ib trial using an individualised standard meal with a fixed nutrient ratio in subjects with type 2...” NCT02562326 ↗62“This study is designed to compare the safety and tolerability of two different doses of intranasally administered regular human insulin with those of a single dose of the...” NCT01201278 ↗ “In order to match peripheral lispro concentrations between study visits, a small dose of Humalog (lispro) insulin will be administered intravenously at 9am, during the placebo...” NCT02131948 ↗ “This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.” NCT00097071 ↗ “Commercially available U-200 Humalog (insulin lispro) diluted 1:1 with a dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration.” NCT07090824 ↗ “Participants can take very short acting insulin (e.g. Humalog or Novolog) up to 2 hours before the test if necessary and then that will be withheld during the test.” NCT01269047 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “EU-authorized Humalog KwikPen® - insulin lispro injection, solution for subcutaneous injection, 100 U/mL (pre-filled).” NCT04254380 ↗ “rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])” NCT00467649 ↗ “Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake” NCT02739906 ↗ “Insulin Lispro (Humalog®) will be administered by subcutaneous injection.” NCT04100473 ↗ “simultaneous injections of insulin lispro (Humalog®) and placebo” NCT03512236 ↗ “Novorapid or Humalog insulin delivered in a basal-bolus manner.” NCT04243629 ↗ “Insulin rapid acting analog (Humalog\*, Novorapid\*)” NCT01756105 ↗ “Insulin lispro, Humalog (Eli Lilly) in insulin pump” NCT01680185 ↗ “Insulin lispro, Humalog (Eli Lilly) in insulin pump” NCT03507829 ↗ “Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra” NCT04965051 ↗ “insulin lispro (Humalog®, Eli Lilly and Company)” NCT02562313 ↗ “Insulin Lispro (Humalog®)” NCT02213146 ↗ “Insulin Lispro (Humalog®)” NCT00071448 ↗ “Humalog (insulin lispro)” NCT00700622 ↗ “Insulin lispro (Humalog)” NCT00356421 ↗ “Insulin lispro (Humalog)” NCT00553488 ↗ “Novorapid or Humalog” NCT02518022 ↗ “Lispro (Humalog)” NCT01686620 ↗ “Novolog/ Humalog” NCT01269034 ↗ “Humalog” NCT02155023 ↗ “Humalog” NCT06419777 ↗ “Humalog” NCT06419803 ↗ “Humalog” NCT03662334 ↗ |
| Known as | Humalog (lispro) | “The insulin (Humalog Lispro 100 IU/ml, Eli Lily, Canada) and placebo (diluent) will be transferred to a metered nasal device” NCT03383822 ↗1“Humalog (lispro)” NCT01378117 ↗ |
| Known as | Humalog 100 IU/mL | “Types of insulin: insulin lispro (Humalog 100 IU/mL) as fast-acting insulin and regular insulin (Humulin R) as regular insulin (Eli Lilly and Company, Indianapolis, IN, USA).” NCT04783376 ↗ |
| Known as | Humalog insulin | “Humalog insulin” NCT01149005 ↗ |
| Known as | Humalog insulin lispro U-100 | “Humalog insulin lispro U-100” NCT02500979 ↗ |
| Known as | Humalog Kwikpen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03328845 ↗ |
| Known as | Humalog U-100 | “Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection” NCT03307512 ↗ |
| Known as | ILPS | “Drug: Insulin Lispro Protamine Suspension (ILPS)” NCT00666718 ↗ |
| Known as | insulin lispro LM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00393705 ↗ |
| Known as | Insulin lispro low mix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00420095 ↗ |
| Known as | Insulin lispro mid mixture (MM) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00377858 ↗ |
| Known as | insulin lispro MM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00393705 ↗ |
| Known as | insulin lispro protamine suspension | “OBJECTIVE: To determine whether metformin-treated patients with type 2 diabetes given an analogue mixture of basal and rapid-acting insulins (insulin lispro protamine...” PMID 19454394 ↗ May 20097“Insulin lispro protamine suspension (Humalog® NPL, Eli Lilly), 100 U/mL in 3 mL cartridges” NCT00810589 ↗ “lispro mix 50/50: 50% insulin lispro protamine suspension and 50% lispro” PMID 17934150 ↗ Oct 2007 |
| Known as | Insulin Lispro Protamine Suspension (ILPS) | “Insulin Lispro Protamine Suspension (ILPS)” NCT00510952 ↗ |
| Known as | LIS | “BACKGROUND: This study was performed to satisfy a US Food and Drug Administration post-marketing requirement to compare the dose responses for Technosphere® Insulin (TI;...” PMID 34773608 ↗ Nov 20211“6 U insulin lispro (LIS) sc on a separate visit” NCT02713841 ↗ |
| Known as | lispro | “In this 20-week trial, adults with T2DM of < 7-years duration were randomized to 8-weeks treatment with (i) insulin glargine (Glar), (ii) glargine + thrice-daily lispro” PMID 36894921 ↗ Mar 202344“Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed” NCT01845831 ↗ “This study compared the pharmacokinetic and glucodynamic parameters of URLi and Lispro (Humalog®) at 3 dose levels in healthy subjects.” PMID 32900535 ↗ Sep 2020 “The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day)” NCT04196231 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump.” NCT02855307 ↗ “Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved.” NCT01974544 ↗ “Humalog (lispro) insulin will be administered intravenously at 9am, during the placebo arm of the study.” NCT02131948 ↗ “Treatment with insulin analogues lispro administered subcutaneously before breakfast, lunch and supper” NCT04690309 ↗ “rapid-acting insulin (lispro or aspart) before meals” NCT02004366 ↗ “Supplemental (correction) lispro or aspart insulin” NCT04416269 ↗ “Prandial Insulins (aspart, glulisine or lispro).” NCT01524705 ↗ “Lantus, Levemir, Novolog, Lispro” NCT02811484 ↗ “Lispro, Aspart, glulisine” NCT04157738 ↗ “Lispro” NCT06419777 ↗ “Lispro” NCT06419803 ↗ “Lispro” NCT04542148 ↗ “Lispro” NCT02012465 ↗ |
| Known as | Lispro Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01045954 ↗ |
| Known as | Lispro Prandial Insulin | “Drug: Lispro Prandial Insulin” NCT06280703 ↗ |
| Known as | LM50 | “AIM: To compare the 2-h postprandial blood glucose (PPBG) excursion following a standard test meal in insulin-requiring patients with diabetes treated twice daily with human...” PMID 18657196 ↗ Jul 2008 |
| Known as | Ly-Lis | “BACKGROUND: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (U100; Humalog®; Ly-Lis).” PMID 29232162 ↗ Dec 2017 |
| Known as | LY900014 | “This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood sugar.” NCT03232983 ↗31 |
| Known as | prandilin | “lispro (prandilin®)” PMID 37735841 ↗ Sep 2023 |
| Known as | Ultra Rapid Lispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06600776 ↗ |
| Known as | URLi | “Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control.” PMID 35577602 ↗ May 20222“Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control.” PMID 34041713 ↗ May 2021 “Ultra Rapid Lispro (URLi)” NCT06600776 ↗ |
| Modality | Protein / enzyme biologic | “fast acting insulin (Lispro)” NCT00046501 ↗ |
| Route | Subcutaneous | “preprandial SC insulin (regular human insulin or insulin lispro)” PMID 17288697 ↗ Feb 2007 |